From Fulcrum Therapeutics press release. Fulcrum plans to launch a Phase 2b clinical trial in FSHD in mid-2019 CAMBRIDGE, Mass., April 23, 2019 – Fulcrum Therapeutics, a biotechnology company focused… Read More »
Fulcrum Acquires Global Rights to a Potential Disease-Modifying Therapy for FSHD
MRI-guided biopsy shows promise for clinical trials
Method may predict DUX4 activity in patients’ muscles A central tenet of modern FSH muscular dystrophy research is that the muscle damage in this disease is caused by a gene… Read More »
Newly funded grants
Steps forward toward new treatments The FSH Society’s board of directors voted to approve $332,906 in funding for three grant applications submitted for the August 2018 cycle. The first project… Read More »
Industry collaborative workshop on FSHD clinical trial readiness
Yesterday, the FSH Society convened a landmark meeting at the Tommy Douglas Conference Center, a stone’s throw from the headquarters of the Food and Drug Administration (FDA). Several FDA regulators… Read More »
Giving a piece of me for research
by HILARY A. C. HOOVER, Ocala, Florida I tested positive for the FSHD gene and am currently asymptomatic. Due to my status, I was asked to donate muscle tissue via open… Read More »